Floatz logo

Daunorubicin

Adult Acute Myeloblastic Leukemia With Maturation (M2)

National Cancer Institute (NCI)Phase 3Dormant
BBB
77/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
68/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Adult Acute Myeloblastic Leukemia With Maturation (M2) cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Stanford University
Phase 3BBB
Cytosin-Arabinosid
Northwestern University
Phase 3BBB
Cytosin-Arabinosid
University of Southern California
Phase 3BBB
Cyclophosphamide
ECOG-ACRIN Cancer Research Group
Phase 3BBB
Idarubicine
Bruno C. Medeiros
Phase 3BBB

View all 50 →

Same molecule, other indications

Daunorubicin is also rated in:

acute myeloid leukemia by FAB classificationDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →